MedTrace Logo

PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients

NCT06610539 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2026-03-16

No results posted yet for this study

Summary

The purpose of this study is to provide prospective evidence in the US population of the frequency of skin discoloration and Sentinel Lymph Node detection rate in patients who have recevied Magtrace for Sentinel Lymph Node Biopsy (SLNB) and to evaluate the impact that skin discoloration has on patients when it does occur using patient reported outcome measures.

Conditions

Sponsors & Collaborators

  • Endomagnetics Inc

    collaborator INDUSTRY

  • Endomagnetics Ltd.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-22
Primary Completion
2028-06-30
Completion
2028-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06610539 on ClinicalTrials.gov